Summarized by Masters of Longevity from Longevity Technology.
An update on an AI-driven drug discovery partnership reaching an early program milestone; a quick look at the collaboration’s research focus and next steps.
Key Takeaways
- Insilico and Servier initiated two oncology R&D programs under a multi-year AI-driven collaboration.
- Insilico completed target nominations for both programs using its Pharma.AI platform.
- An undisclosed milestone payment was triggered when Insilico reached the first program milestone.
